Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Doherty

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Brain : a Journal of Neurology|August 25, 2020
Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitisFrancesco Mannara, Marija Radosevic, Jesús Planagumà, et al.
Surgical Infections|January 26, 2006
The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective studyCarl I Schulman, Nicholas Namias, James Doherty, et al.
Journal of Neurochemistry|February 16, 2013
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humansBiljana Georgievska, Johan Sandin, James Doherty, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 24, 2023
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL studySagar V Parikh, Scott T Aaronson, Sanjay J Mathew, et al.
Lancet (London, England)|June 17, 2017
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trialStephen Kanes, Helen Colquhoun, Handan Gunduz-Bruce, et al.
Physical Chemistry Chemical Physics : PCCP|January 19, 2019
Anticancer drug impact on DNA - a study by neutron spectroscopy coupled with synchrotron-based FTIR and EXAFSAna L M Batista de Carvalho, Adriana P Mamede, Asha Dopplapudi, et al.
Lancet (London, England)|December 11, 2007
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studiesRajesh Krishna, Matt S Anderson, Arthur J Bergman, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Brain : a Journal of Neurology|August 25, 2020
Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitisFrancesco Mannara, Marija Radosevic, Jesús Planagumà, et al.
Surgical Infections|January 26, 2006
The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective studyCarl I Schulman, Nicholas Namias, James Doherty, et al.
Journal of Neurochemistry|February 16, 2013
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humansBiljana Georgievska, Johan Sandin, James Doherty, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 24, 2023
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL studySagar V Parikh, Scott T Aaronson, Sanjay J Mathew, et al.
Lancet (London, England)|June 17, 2017
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trialStephen Kanes, Helen Colquhoun, Handan Gunduz-Bruce, et al.
Physical Chemistry Chemical Physics : PCCP|January 19, 2019
Anticancer drug impact on DNA - a study by neutron spectroscopy coupled with synchrotron-based FTIR and EXAFSAna L M Batista de Carvalho, Adriana P Mamede, Asha Dopplapudi, et al.
Lancet (London, England)|December 11, 2007
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studiesRajesh Krishna, Matt S Anderson, Arthur J Bergman, et al.
Pageof 5